Regency Capital Management Inc. DE Takes $3.70 Million Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Regency Capital Management Inc. DE acquired a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 7,114 shares of the medical research company’s stock, valued at approximately $3,701,000. Thermo Fisher Scientific makes up about 2.0% of Regency Capital Management Inc. DE’s investment portfolio, making the stock its 22nd biggest position.

A number of other institutional investors also recently made changes to their positions in TMO. Archford Capital Strategies LLC increased its stake in shares of Thermo Fisher Scientific by 2.0% in the fourth quarter. Archford Capital Strategies LLC now owns 4,101 shares of the medical research company’s stock worth $2,134,000 after buying an additional 80 shares during the last quarter. AlphaMark Advisors LLC increased its position in shares of Thermo Fisher Scientific by 3.2% in the 4th quarter. AlphaMark Advisors LLC now owns 2,308 shares of the medical research company’s stock worth $1,201,000 after purchasing an additional 72 shares during the last quarter. Patton Albertson Miller Group LLC lifted its position in shares of Thermo Fisher Scientific by 3.6% during the fourth quarter. Patton Albertson Miller Group LLC now owns 14,446 shares of the medical research company’s stock worth $7,515,000 after purchasing an additional 500 shares during the last quarter. Insight Inv LLC bought a new stake in Thermo Fisher Scientific in the fourth quarter valued at about $332,000. Finally, Monte Financial Group LLC lifted its holdings in Thermo Fisher Scientific by 2.6% during the 4th quarter. Monte Financial Group LLC now owns 2,270 shares of the medical research company’s stock worth $1,181,000 after buying an additional 57 shares during the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $554.29, for a total value of $5,542,900.00. Following the completion of the transaction, the chief executive officer now owns 121,192 shares of the company’s stock, valued at approximately $67,175,513.68. This trade represents a 7.62 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders sold 44,850 shares of company stock valued at $24,666,097. 0.34% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Stock Performance

Shares of TMO opened at $575.21 on Friday. Thermo Fisher Scientific Inc. has a 12-month low of $493.30 and a 12-month high of $627.88. The stock has a market capitalization of $220.02 billion, a P/E ratio of 36.06, a P/E/G ratio of 3.82 and a beta of 0.76. The firm’s 50 day moving average is $533.60 and its 200-day moving average is $569.32. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.63 and a quick ratio of 1.26.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.25 by $0.03. The company had revenue of $10.60 billion for the quarter, compared to analysts’ expectations of $10.63 billion. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The firm’s revenue was up .2% on a year-over-year basis. During the same quarter in the prior year, the company earned $5.69 earnings per share. Equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.69 EPS for the current fiscal year.

Thermo Fisher Scientific announced that its Board of Directors has approved a stock buyback program on Friday, November 15th that allows the company to repurchase $4.00 billion in shares. This repurchase authorization allows the medical research company to buy up to 2% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s leadership believes its stock is undervalued.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, January 15th. Investors of record on Friday, December 13th were paid a $0.39 dividend. The ex-dividend date was Friday, December 13th. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio is currently 9.78%.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on TMO. Royal Bank of Canada dropped their price target on Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating on the stock in a research report on Thursday, October 24th. Bernstein Bank raised their price target on shares of Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a “market perform” rating in a research report on Tuesday, October 22nd. Redburn Atlantic initiated coverage on shares of Thermo Fisher Scientific in a research report on Monday, October 14th. They set a “buy” rating and a $680.00 price objective for the company. Scotiabank assumed coverage on Thermo Fisher Scientific in a report on Monday, December 23rd. They set a “sector perform” rating and a $605.00 target price for the company. Finally, Evercore ISI cut their price target on Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. Four investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $648.95.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.